Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA studyMarina Elena Cazzaniga, Martina Dester, Mario Airoldi et al.|The Breast|2017Cited by 23
A Phase II Study of Olaparib in Breast Cancer Patients: Biological Evaluation from a ‘Window of Opportunity’ TrialGiandomenico Roviello, Daniele Generali, Carla Strina et al.|Future Oncology|2016Cited by 10
Early Changes of the Standardized Uptake Values (SUVmax) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast CancerMarianna Sirico, Daniele Generali, Ottavia Bernocchi et al.|Cancers|2020Cited by 9
Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET studySilvia Paola Corona, Daniele Generali, Fabiola Giudici et al.|Oncotarget|2020Cited by 8
Assessing the long-term prognostic ability of the 70 gene expression signature MammaPrint in an Italian single-center prospective cohort study of early-stage intermediate-risk breast cancer patientsDaniele Generali, Stannie J. van den Ende, Andrea Rocca et al.|Heliyon|2024Cited by 1